Key Highlights

  • ATEC shares are trading up 19.12% to $10.53.
  • A regulatory filing revealed CEO Patrick Miles purchased 115,000 shares for roughly $1.01 million at prices between $8.73 and $8.84.
  • The purchase comes after the stock had fallen about 58% year to date and was trading near its 52-week low of $6.82.
  • The company highlighted strong procedural Volume growth and surgeon adoption at the Wells Fargo Healthcare Conference this week.
  • Second-quarter Revenue grew 15% to $214 million, with a raised full-year outlook.

A CEO Buys Near the Bottom

There's a particular kind of signal that comes from an executive putting personal money into a stock that's down more than half for the year, and that's exactly what's driving Alphatec Holdings (NASDAQ:ATEC) higher today. A regulatory filing revealed that CEO Patrick Miles purchased 115,000 shares for roughly $1.01 million at prices between $8.73 and $8.84, a notable vote of confidence given the stock had fallen approximately 58% year to date and was trading near its 52-week low of $6.82 at the time.

Insider Buying Follows Upbeat Conference Commentary

The insider purchase comes on the heels of upbeat commentary at the Wells Fargo Healthcare Conference this week, where the company highlighted strong procedural volume growth, surgeon adoption trends, and product innovation tied to its Valence navigation and robotics system, supporting long-term guidance through 2027. Alphatec Holdings is a medical technology company dedicated exclusively to developing technologies for the surgical treatment of spinal disorders, operating through its Alphatec Spine, EOS imaging, and SafeOp Surgical subsidiaries.

A Quarter That Already Showed Momentum

The buying interest builds on a solid second-quarter print showing 15% revenue growth to $214 million and a raised full-year outlook, results that had not fully translated into share price strength before today's insider disclosure. That gap between improving fundamentals and a depressed stock price appears to be part of what convinced Miles to buy in personally.

Volume Surge Reflects Broad Investor Interest

Trading volume of over 4.3 million shares versus an average of 2.45 million underscores heightened investor interest in today's move, which coincides with broader medical device sector strength as peers Inspire Medical (NYSE:INSP) and AtriCure (NASDAQ:ATRC) also posted gains. Continued execution against the 2027 guidance reaffirmed this week will likely be the key Factor determining whether today's rally holds.